Correction to: Andexanet Alfa: First Global Approval

被引：0

|

作者：

Young-A Heo

机构：

[1] Springer,

来源：

Drugs | 2018年 / 78卷 / 12期

关键词：

D O I：

10.1007/s40265-018-0954-y

中图分类号：

学科分类号：

摘要：

The article Andexanet Alfa: First Global Approval, written by Young-A Heo, was originally published Online First without open access.

引用

收藏

页码：1285 / 1285

相关论文

共 50 条

[31] Olipudase Alfa: First Approval
Susan J. Keam
Drugs, 2022, 82 : 941 - 947
[32] Avalglucosidase alfa: First Approval
Sohita Dhillon
Drugs, 2021, 81 : 1803 - 1809
[33] Cipaglucosidase Alfa: First Approval
Hannah A. Blair
Drugs, 2023, 83 (8) : 739 - 745
[34] Apadamtase Alfa: First Approval
Heo, Young-A.
DRUGS, 2024, 84 (03) : 275 - 284
[35] Avalglucosidase alfa: First Approval
Dhillon, Sohita
DRUGS, 2021, 81 (15) : 1803 - 1809
[36] Olipudase Alfa: First Approval
Keam, Susan J.
DRUGS, 2022, 82 (08) : 941 - 947
[37] FDA Approval of Andexanet Alfa Based on a Single-Arm Trial: If There Is a Villain, Who Is It?
Pallin, Daniel J.
ANNALS OF EMERGENCY MEDICINE, 2019, 74 (05) : 725 - 727
[38] Andexanet alfa in acute aortic syndrome: first UK experience
Al-Attara, Nawwar
Sedeeka, Ahmed F.
McCallb, Philip
Traversc, Jennifer
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2023, 63 (06)
[39] Nogapendekin alfa Inbakicept: First Approval
Keam, Susan J.
DRUGS, 2024, 84 (07) : 867 - 874
[40] FDA Approval of Andexanet Alfa Based on a Single-Arm Trial: If There Is a Villain, Who Is It? reply
Radecki, Ryan P.
Spiegel, Rory J.
Wang, Henry E.
ANNALS OF EMERGENCY MEDICINE, 2019, 74 (05) : 727 - 727

← 1 2 3 4 5 →